albuterol and Acute Respiratory Distress Syndrome

albuterol has been researched along with Acute Respiratory Distress Syndrome in 37 studies

Albuterol: A short-acting beta-2 adrenergic agonist that is primarily used as a bronchodilator agent to treat ASTHMA. Albuterol is prepared as a racemic mixture of R(-) and S(+) stereoisomers. The stereospecific preparation of R(-) isomer of albuterol is referred to as levalbuterol.
albuterol : A member of the class of phenylethanolamines that is 4-(2-amino-1-hydroxyethyl)-2-(hydroxymethyl)phenol having a tert-butyl group attached to the nirogen atom. It acts as a beta-adrenergic agonist used in the treatment of asthma and chronic obstructive pulmonary disease (COPD).

Research

Studies (37)

Authors

Clinical Trials (4)

Trial Overview

Trial Outcomes

Hospital Mortality to Day 60 in the Subset of Participants With ARDS

Difference in the main outcome mortality to study day 60 was calculated for the subset of patients with ARDS (defined as a PaO2/FiO2 ratio of less than or equal to 200) prior to randomization. P/F ratio is an index of the effectiveness of arterial oxygenation that corresponds to the ratio of partial pressure of arterial O2 to the fraction of inspired O2. (NCT00434993)
Timeframe: Determined 60 days after a subject entered the study

Hospital Mortality up to Day 60 in Subjects With Baseline Shock

Difference in the main outcome hospital mortality to study day 60 was calculated for the subset of patients who were in shock at the time of randomization. Shock was defined as mean arterial pressure<60 or the need for vasopressors (except dopamine <6 ug/kg/min). (NCT00434993)
Timeframe: Determined 60 days after a subject entered the study

Mortality Prior to Hospital Discharge With Unassisted Breathing to Day 60

Success for this efficacy variable was defined as being alive on study day 60 or having been discharged alive off mechanical ventilation from the study hospital (or subsequent hospital) to the subject's original place of residence. Those subjects alive in hospital at day 60 were considered to have survived. (NCT00434993)
Timeframe: Determined 60 days after a subject entered the study

Mortality Prior to Hospital Discharge With Unassisted Breathing to Day 90

Success for this efficacy variable was defined as being alive on study day 90 or having been discharged alive off mechanical ventilation from the study hospital (or subsequent hospital) to the subject's original place of residence. Those participants who still remained in the hospital at 90 days after randomization were considered to have survived. (NCT00434993)
Timeframe: Determined 90 days after a subject entered the study

Number of ICU-free Days at 28 Days After Randomization

ICU (intensive care unit)-free days was defined as the number of days a subject was out of the ICU during study hospitalization from date of randomization up to study day 28. All incidences of ICU admission and discharge during the study hospitalization were captured. Any portion of a calendar day that a subject was in the ICU was counted as an ICU day. (NCT00434993)
Timeframe: Determined 28 days after a subject entered the study

Number of Organ Failure-free Days at Day 28 Following Randomization

Subjects were followed for development of organ failures from date of randomization to hospital discharge or study day 28, whichever was first. Organ failure was defined as present on any calendar day when the most abnormal vital signs or clinically available lab value met the definition of clinically significant organ failure according to the Brussels Organ Failure Table. Each day a patient was alive and free of a given clinically significant organ failure was scored as a failure-free day. The worst value for a calendar day was captured (lowest systolic BP, platelet count and highest creatinine and bilirubin values). Specific definitions of organ failure were: cardiovascular-systolic BP less than or equal to 90 mmHg or on a vasopressor; coagulation-platelet count less than or equal to 80 x 1000/mm3; Renal-creatinine less than or equal to 2.0 mg/dL; Hepatic-bilirubin less than or equal to 2.0 mg/dL. (NCT00434993)
Timeframe: Daily from baseline to study day 28

Number of Ventilator Free Days (VFD)

Ventilator-free days (VFDs) is defined as the number of days from randomization to Day 28 after achieving unassisted breathing for patients who maintained unassisted breathing for at least two consecutive calendar days. If a patient achieved unassisted breathing, subsequently required additional assisted breathing, and once again achieved unassisted breathing, we counted only the VFDs after beginning the final period of unassisted breathing. Patients who died before Day 28 were assigned zero VFDs. (NCT00434993)
Timeframe: Determined 28 days after a subject entered the study

Ventilator Free Days to Day 28 in the Subset of Participants With ARDS

Difference in the main outcome Ventilator Free Days to study day 28 was calculated for the subset of patients with ARDS (defined as a PaO2/FiO2 ratio of less than or equal to 200). P/F ratio is an index of the effectiveness of arterial oxygenation that corresponds to the ratio of partial pressure of arterial O2 to the fraction of inspired O2. VFD to Day 28 is defined as the number of days from the end of ventilation to day 28 in patients who maintained unassisted breathing for at least two consecutive calendar days. Patients who died before day 28 were assigned a VFD count of zero. If a patient returned to assisted breathing, subsequently required assisted breathing, and once again achieved unassisted breathing, only the VFDs after beginning the final period of unassisted breathing were counted. An increase in the number of VFDs was considered a positive result. (NCT00434993)
Timeframe: Determined 28 days after a subject entered the study

Ventilator Free Days to Day 28 in the Subset of Patients With Baseline Shock

Difference in the main outcome Ventilator Free Days to study day 28 was calculated for the subset of patients who were in shock at the time of randomization. Shock was defined as mean arterial pressure<60 or the need for vasopressors (except dopamine <6 ug/kg/min). (NCT00434993)
Timeframe: Determined 28 days after a subject entered the study

Plasma Levels of IL-6 and IL-8 on Study Day 3

Biologic end-points were selected that would provide mechanistic insight into how albuterol improved lung function. Concentrations of two proinflammatory cytokines, interleukin 6 and 8 (IL-6 and IL-8), were measured. Plasma was collected and cytokine levels were measured at baseline and 3 days after randomization. IL-6 and IL-8 levels were normalized using log transformation. Wilcoxon's test was used to compare mean log-transformed interleukin levels per day and a mixed-effects model was fit to compare the slopes. (NCT00434993)
Timeframe: Measured at baseline and 3 days after randomization

Donor Oxygenation

The primary outcome was the change in oxygenation as measured by change in the PaO2/FiO2 ratio from study enrollment to organ procurement (NCT00310401)
Timeframe: Change from enrollment to organ procurement (about ~40h after enrollment)

Number of Donor Lungs Used for Transplantation

Number of lungs procured and used for transplantation (NCT00310401)
Timeframe: 72 hours

Chest X-ray Findings

Chest radiographs were scored using a radiographic score that scored each quadrant for extent of radiographic infiltrates on a scale of 0 to 4, then summed each quadrant for a total score from 0 (no infiltrates) to 16 (extensive infiltrates in all 4 radiographic quadrants). (NCT00310401)
Timeframe: change from enrollment to organ procurement (about ~40h after enrollment)

Lung Compliance

Static compliance of the respiratory system using plateau pressure (Pplat) measured at end-inspiration and calculated using the equation static compliance = tidal volume/(Pplat - PEEP) (NCT00310401)
Timeframe: baseline and at organ procurement (about ~40h after enrollment)

Reviews

2 reviews available for albuterol and Acute Respiratory Distress Syndrome

Trials

7 trials available for albuterol and Acute Respiratory Distress Syndrome

Other Studies

28 other studies available for albuterol and Acute Respiratory Distress Syndrome